BOARD OF DIRECTORS
Remi BarbierChairman of the Board, President & CEO
Remi Barbier, the Company’s founder, has served as President, Chief Executive Officer and Chairman of the Board of Directors since the Company’s inception in May 1998. Prior to that time, Mr. Barbier helped in the growth or founding of Exelixis Inc., a publicly-traded drug development company, ArQule, Inc., a drug development company acquired by Merck & Co., and EnzyMed, Inc., a chemistry company sold to Albany Molecular Research, Inc. Mr. Barbier is a trustee emeritus of the Carnegie Institute of Washington, the Santa Fe Institute and the Advisory Board of the University of California Institute for Quantitative Biosciences. He is on the board of BioVentures LLC, a life science incubator at the University of Arkansas for Medical Sciences.Chairman of the Board
Richard J. Barry
Richard (Rick) Barry has served as a Director since June 2021. Since June 2015, Mr. Barry has also served as Director of Sarepta Therapeutics, Inc., (Nasdaq: SRPT). Mr. Barry has extensive experience in the investment management business. He was a founding member of Eastbourne Capital Management LLC, and served as a Managing General Partner and Portfolio Manager from 1999 to its close in 2010. Prior to Eastbourne, Mr. Barry was a Portfolio Manager and Managing Director of Robertson Stephens Investment Management. Mr. Barry holds a Bachelor of Arts from Pennsylvania State University.Independent Director
Nadav Friedmann PhD, MDChief Medical Officer
Dr. Nadav Friedmann joined SAVA as Chief Medical Officer in October 2001 and has served as a director since September 1998. Dr. Friedmann was previously President and CEO of Daiichi Pharmaceutical Corporation. Dr. Friedmann has served as Vice President, Clinical Research at Xoma Corporation, and held various senior leadership positions with Johnson & Johnson, including Head of its Biotechnology Research Center.
Robert Gussin PhD
Dr. Gussin has served as a director since March 2003. Dr. Gussin worked at J&J for 26 years, most recently as Chief Scientific Officer and Corporate Vice President, Science and Technology from 1986 through his retirement in 2000. Dr. Gussin served on the Board of Directors of Duquesne University and the advisory boards of the Duquesne University Pharmacy School and the University of Michigan Medical School Department of Pharmacology.Independent Director
Michael O'Donnell Esq.
Michael O'Donnell has served as a director since June 1998. Mr. O'Donnell is a partner in the law firm of Orrick, Herrington & Sutcliffe LLP, SAVA's corporate counsel. Mr. O'Donnell received a JD degree, cum laude, from Harvard University and a BA degree from Bucknell University, summa cum laude.Independent Director
Sanford Robertson has served as a director since 1998. Mr. Robertson has been a partner of Francisco Partners, a technology buyout fund, since 1999. Prior to founding Francisco Partners, Mr. Robertson was the founder and chairman of Robertson, Stephens & Company, a technology investment bank sold to BankBoston in 1998. Mr. Robertson is the lead director of Salesforce.com, a publicly-held provider of enterprise cloud computing applications.Independent DirectorLead Director
Patrick Scannon MD, PhD
Dr. Pat Scannon has served as a director since 2007. Dr. Scannon is one of the founders of XOMA Corporation. From 2006 to 2016, Dr. Scannon was Executive Vice President, Chief Biotechnology Officer of XOMA. From 1993 to 2006, Dr. Scannon served as Chief Scientific and Medical Officer of XOMA.Independent Director